Navigation Links
Bradmer announces 2008 third quarter operational and financial results


TORONTO, Nov. 10 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a clinical oncology company specializing in the development and commercialization of cancer therapies, today announced its 2008 third quarter operational and financial results.

Operational Highlights

During the three months ended September 30, 2008 and the period subsequent to this date, the Company achieved the following milestones related to its operations and its lead drug, Neuradiab(TM), which is being studied in the Phase III GLASS-ART(TM) Trial:

- Maintained budgetary control and reduced quarterly spending;

- Signed clinical study contracts with nine of the initial 16 sites

under active consideration and activated an initial cohort of five

sites, while advancing a pipeline of additional sites in the US

through the contractual, training and regulatory process;

- Initiated dialog with Health Canada for study expansion into key

Canadian sites with the support of the Canadian Brain Cancer


- Enrolled the first group of patients in the GLASS-ART Trial and

successfully dosed patients with Neuradiab at multiple sites;

- Announced new data from the most recent Phase II trial indicating that

the mean time to progression free survival was 77 weeks, which

compares favorably with other published results in newly diagnosed


- Evaluated a series of technical steps that may allow a two week

extension of the shelf life of Neuradiab beyond the current six-day

specification; and

- Appointed Dr. Donald Kufe, Professor of Medicine, Harvard Medical

School and Director, Experimental Therapeutics Program, Dana-

Farber/Harvard Cancer Center and Charles James Lilly, CA, a senior

partner with a public accounting firm, to the Board of Directors of

the Company.

"The treat

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Bradmer to present at Rodman & Renshaw Healthcare Conference
2. Bradmer receives FDA approval to proceed with Phase III clinical trial
3. Bradmer announces 2008 first quarter operational and financial results
4. Bradmer announces new additions to management team
5. Bradmer announces 2007 fourth quarter and fiscal year operational and financial results
6. Notice of Bradmer Pharmaceuticals Conference Call
7. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
8. Bradmer to present at the 10th Annual BIO CEO & Investor Conference
9. Bradmer announces additions to Scientific Advisory Board
10. Bradmer Medical Isotope Supply For Phase III Trial Secure
11. Bradmer to present at Rodman & Renshaw Healthcare Conference
Post Your Comments:
(Date:7/10/2014)... Up to 70% of Parkinson,s disease (PD) patients ... of life. Some patients have disturbed sleep/wake patterns ... while other patients may be subject to sudden ... PD patients may exhibit REM-sleep behavior disorder (RBD), ... even before motor symptoms appear. A review in ...
(Date:7/10/2014)... the human brain operates much the same whether active ... a better understanding of schizophrenia, bipolar disorder and other ... million Americans. , In newly published research in the ... at the Center for Molecular and Behavioral Neuroscience, determined ... rest is basically the same as that of a ...
(Date:7/10/2014)... Manchester scientists have shown that a new drug could prove ... aggressive form of lung cancer. , Scientists from the Cancer ... and part of the Manchester Cancer Research Centre, teamed up ... in 2010, to test a drug known as AZD3965 ... published in the journal Clinical Cancer Research , also ...
(Date:7/9/2014)... July 10, 2014 For the first time, researchers ... Aboriginal population in Canada uses health care. A new ... to clearly demonstrate the unique challenges faced by urban ... St. Michael,s Hospital. , The findings, published today ... urban First Nations individuals and the general population. , ...
(Date:7/9/2014)... hidden ways that cells are regulated, scientists at Rockefeller ... cells more likely to metastasize. , What,s more, the ... blocking two other proteins that are normally linked to ... could have unexpected ties. , The study, which ... , points to the possibility of new cancer therapies ...
Breaking Medicine News(10 mins):Health News:Sleep disturbances, common in Parkinson's disease, can be early indicator of disease onset 2Health News:Working to loosen the grip of severe mental illness 2Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Urban Aboriginal people face unique health challenges 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3
... Alzheimer's disease and is connected to the same brain pathology. There ... cognitive decline the loss of memory and certain other aspects of ... a normal part of aging, others that it is an early ... it's a disease in its own right. ,A new ...
... the combination of just two genes, according to a new study ... of Clinical Endocrinology and Metabolism this week,// identifies one gene on ... height in men. These genes may also help explain why men ... of both of these genes you will be taller than a ...
... serum concentrations of estrogen and testosterone have about twice ... relatively low serum concentrations of these sex hormones. Associations ... breast cancer were not different in women who donated ... levels in these women were not a preclinical finding. ...
... A new US research has found that young women are ... young men.The study, which contradicts the stereotype that men// are ... The Annals of Internal Medicine this week. ,Researchers from ... years after they were discharged from hospital after a heart ...
... the liver from damage, according to new research from ... laboratory rats. //The rats were then given D-galactosamine, a ... synthesis and results in cell death. The rats fed ... ,The Researchers discovered three new compounds that might ...
... drugs called statins may reduce their risk of developing ... to offer// powerful protection against heart disease for people ... evidence to date that statin drugs may also help ... smaller study had suggested these drugs might offer some ...
Cached Medicine News:
(Date:1/15/2014)... Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ...
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment ... Chief Executive Officer.  Mark was promoted from his current role ... company,s four facilities in Massachusetts , ... Tegra Medical in 2012 with 20+ years of broad-based operations, ...
(Date:1/15/2014)... 15, 2014  According to Millennium Research Group (MRG), ... the United States and ... will expand moderately through 2022, with embolization particles ... increasing interest in drug-eluting beads (DEBs) and radioembolization ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... St. Jude scientists, findings in ataxia telangiectasia-like ... into the links between brain disease and ... Tenn., Jan. 14 Scientists ... teased apart the biological details distinguishing two ...
... first quarterKENILWORTH, N.J., Jan. 14 Schering-Plough Corporation (NYSE: ... Food and Drug Administration (FDA) has issued a complete ... acute treatment of schizophrenia in adults and in the ... bipolar I disorder in adults as monotherapy. The ...
Cached Medicine Technology:Study Shows How Defective DNA Repair Triggers Two Neurological Diseases 2Study Shows How Defective DNA Repair Triggers Two Neurological Diseases 3U.S. FDA Issues Complete Response Letter for SAPHRIS(TM) (ASENAPINE) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder 2
A system for the removal and filtration of laser and surgical smoke....
The FreedomAire Surgical Helmet System is a lightweight, comfortable helmut system with superior air flow, and a removable motor module that lifts off for easy cleaning....
... contains these disposable, silver/silver chloride ... separated into eight tabs), two ... patient use only. Starter kit ... red and black, one green ...
Medicine Products: